Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Promacta, Revolade
Eltrombopag is a thrombopoietin receptor agonist used to treat thrombocytopenia (low platelet count). It stimulates the production of platelets in the bone marrow, helping to prevent bleeding complications. It's primarily prescribed for chronic immune thrombocytopenia (ITP) and aplastic anemia. It's available as both an oral tablet and an oral suspension.
Used to treat thrombocytopenia (low platelet count) in adults and children with chronic immune thrombocytopenia (ITP), aplastic anemia, and other conditions.
Hepatotoxicity and development or worsening of pre-existing hepatic disease, including hepatic failure leading to death or the need for liver transplantation, have been reported in patients receiving eltrombopag. Increased risk of thromboembolic complications reported in patients with chronic liver disease.
Outcome:
Increased bleeding risk
Mechanism:
Altered metabolism
Outcome:
Potential increased risk of liver toxicity
Mechanism:
Additive effects on liver enzymes
Outcome:
No clinically significant interaction expected
Mechanism:
Different metabolic pathways
Most likely new formulation: Extended-release formulation (Year: 2026, 75% confidence)
Based on current usage and clinical trial data, there is a 90% likelihood of eltrombopag remaining a first-line treatment for chronic ITP.
Thrombopoietin Receptor Agonist, Hematopoietic Agent
Non-peptide thrombopoietin mimetic